Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry: New SOFTWARE Act Provides Certainty

This article was originally published in The Gray Sheet

Executive Summary

Rep. Blackburn’s SOFTWARE Act has changed substantially since it was first introduced and is being praised by device manufacturers for providing much needed clarity on how far FDA can go to regulate Medical and Health software.

You may also be interested in...



Updated SOFTWARE Act: Still Too Ambiguous For Industry?

While some industry experts say the updated version of the SOFTWARE Act strikes a tenable balance between industry's need for certainty and FDA's need to ensure patient safety, others argue it does not go far enough to explicitly state what kinds of health IT software the agency will not regulate.

Updated SOFTWARE Act: Still Too Ambiguous For Industry?

While some industry experts say the updated version of the SOFTWARE Act strikes a tenable balance between industry's need for certainty and FDA's need to ensure patient safety, others argue it does not go far enough to explicitly state what kinds of health IT software the agency will not regulate.

Fewer Device Submissions Sought In Subcommittee-Passed 'Cures' Bill

The House Energy & Commerce Health Subcommittee moved the 21st Century Cures bill forward in a May 14 mark. The legislation includes a newly fleshed-out measure allowing third-party quality systems certifications to replace certain PMA supplements, and another focused on exempting more devices from 510(k)s.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel